BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 11801915)

  • 1. Functioning acinar cell pancreatic carcinoma: diagnosis on mangafodipir trisodium (Mn-DPDP)-enhanced MRI.
    Sahani D; Prasad SR; Maher M; Warshaw AL; Hahn PF; Saini S
    J Comput Assist Tomogr; 2002; 26(1):126-8. PubMed ID: 11801915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Magnetic resonance with manganese-DPDP (mangafodipir) of focal solid pancreatic lesions.
    Zanello A; Nicoletti R; Brambilla P; Boccuni R; Di Carlo V; Staudacher C; Del Maschio A
    Radiol Med; 2004 Sep; 108(3):194-207. PubMed ID: 15343134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mangafodipir trisodium (MnDPDP)-enhanced magnetic resonance imaging of the liver and pancreas.
    Wang C
    Acta Radiol Suppl; 1998; 415():1-31. PubMed ID: 9571956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mangafodipir trisodium injection (Mn-DPDP). A contrast agent for abdominal MR imaging.
    Rofsky NM; Earls JP
    Magn Reson Imaging Clin N Am; 1996 Feb; 4(1):73-85. PubMed ID: 8673718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MRI with mangafodipir trisodium in the detection of pancreatic tumours: comparison with helical CT.
    Rieber A; Tomczak R; Nüssle K; Klaus H; Brambs HJ
    Br J Radiol; 2000 Nov; 73(875):1165-9. PubMed ID: 11144793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [MR imaging of pancreatic lesions with Mn-DPDP. A histopathologic correlation].
    Dobritz M; Fellner FA; Baum U; Nömayr A; Lell M; Klein P; Papadopoulos T; Bautz W
    Rofo; 2002 Jul; 174(7):893-7. PubMed ID: 12101481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mangafodipir-DPDP enhanced MRI visualization of a pancreatic adenocarcinoma previously undetected by extracellular contrast enhanced CT and MRI.
    De Filippo M; Bocchi C; Quartieri L; Corradi D; Zompatori M
    Acta Biomed; 2007 Dec; 78(3):225-8. PubMed ID: 18330084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pancreatic enhancement and pulse sequence analysis using low-dose mangafodipir trisodium.
    Mayo-Smith WW; Schima W; Saini S; Slater GJ; McFarland EG
    AJR Am J Roentgenol; 1998 Mar; 170(3):649-52. PubMed ID: 9490946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of the hepatobiliary contrast agent mangafodipir trisodium (MN-DPDP) on the imaging properties of abdominal organs.
    Jung G; Heindel W; Krahe T; Kugel H; Walter C; Fischbach R; Klaus H; Lackner K
    Magn Reson Imaging; 1998 Oct; 16(8):925-31. PubMed ID: 9814775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MR imaging of pancreatic lesions. Comparison of manganese-DPDP and gadolinium chelate.
    Diehl SJ; Lehmann KJ; Gaa J; McGill S; Hoffmann V; Georgi M
    Invest Radiol; 1999 Sep; 34(9):589-95. PubMed ID: 10485075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MRI for detection of hepatocellular carcinoma: comparison of mangafodipir trisodium and gadopentetate dimeglumine contrast agents.
    Youk JH; Lee JM; Kim CS
    AJR Am J Roentgenol; 2004 Oct; 183(4):1049-54. PubMed ID: 15385303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unexpected MR-T1 enhancement of endocrine liver metastases with mangafodipir.
    Mathieu D; Coffin C; Kobeiter H; Caseiro-Alves F; Mahfouz A; Rahmouni A; Diche T
    J Magn Reson Imaging; 1999 Aug; 10(2):193-5. PubMed ID: 10441024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mangafodipir trisodium-enhanced magnetic resonance imaging for evaluation of pancreatic mass and mass-like lesions.
    Eser G; Karabacakoglu A; Karakose S; Eser C; Kayacetin E
    World J Gastroenterol; 2006 Mar; 12(10):1603-6. PubMed ID: 16570354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contrast-enhanced MRI of the liver with mangafodipir trisodium: imaging technique and results.
    Sahani DV; O'Malley ME; Bhat S; Hahn PF; Saini S
    J Comput Assist Tomogr; 2002; 26(2):216-22. PubMed ID: 11884777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatocellular carcinoma: MR imaging with mangafodipir trisodium (Mn-DPDP).
    Murakami T; Baron RL; Peterson MS; Oliver JH; Davis PL; Confer SR; Federle MP
    Radiology; 1996 Jul; 200(1):69-77. PubMed ID: 8657947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benign and malignant hepatocellular tumors: evaluation of tumoral enhancement after mangafodipir trisodium injection on MR imaging.
    Coffin CM; Diche T; Mahfouz A; Alexandre M; Caseiro-Alves F; Rahmouni A; Vasile N; Mathieu D
    Eur Radiol; 1999; 9(3):444-9. PubMed ID: 10087113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of exocrine cells in pancreatic enhancement using Mn-DPDP-enhanced MR imaging.
    Gong J; Xu J; Zhou K; Shen K
    Chin Med J (Engl); 2002 Sep; 115(9):1363-6. PubMed ID: 12411113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MRI measurement of hepatocyte toxicity using the new MRI contrast agent manganese dipyridoxal diphosphate, a manganese/pyridoxal 5-phosphate chelate.
    Young SW; Simpson BB; Ratner AV; Matkin C; Carter EA
    Magn Reson Med; 1989 Apr; 10(1):1-13. PubMed ID: 2502699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MRI with mangafodipir trisodium in the detection and staging of pancreatic cancer.
    Romijn MG; Stoker J; van Eijck CH; van Muiswinkel JM; Torres CG; Laméris JS
    J Magn Reson Imaging; 2000 Aug; 12(2):261-8. PubMed ID: 10931589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mangafodipir trisodium-enhanced MR imaging of pancreatic disease.
    Boraschi P; Donati F; Gigoni R; Caramella D; Boggi U; Falaschi F; Bartolozzi C
    Eur Radiol; 2006 May; 16(5):988-97. PubMed ID: 16421713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.